Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.

Bhorat, As'ad E; Madhi, Shabir A; Laudat, France; Sundaraiyer, Vani; Gurtman, Alejandra; Jansen, Kathrin U; Scott, Daniel A; Emini, Emilio A; Gruber, William C; Schmoele-Thoma, Beate

Bhorat, As'ad E; Madhi, Shabir A; Laudat, France; Sundaraiyer, Vani; Gurtman, Alejandra; Jansen, Kathrin U; Scott, Daniel A; Emini, Emilio A; Gruber, William C; Schmoele-Thoma, Beate.

Affiliation

Bhorat AE; aSoweto Clinical Trials Centre bMedical Research Council: Respiratory and Meningeal Pathogens Research Unit & Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of Witwatersrand, Johannesburg, South Africa cPfizer Vaccine Research, Pearl River, New York dInVentiv Health Clinical, LLC, Princeton, New Jersey, USA ePfizer Pharma, GmbH, Berlin, Germany.

AIDS ; 29(11): 1345-54, 2015 Jul 17.

Article de En | MEDLINE | ID: mdl-25888646

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Infections à pneumocoques / Streptococcus pneumoniae / Infections à VIH / Vaccins antipneumococciques / Anticorps antibactériens Type d'étude: Clinical_trials Limites: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Langue: En Journal: AIDS Sujet du journal: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Année: 2015 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google